ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide
August 08 2022 - 12:29PM
Business Wire
- First-of-its-kind platform provides publicly-accessible,
quarterly data trends on adult vaccination to strengthen data
transparency and empower the public health community with
actionable information
- Vaccine Track data insights revealed sustained decline of
recommended adult immunizations, excluding flu vaccinations, across
the US during the pandemic, especially in minority populations
GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine
Track, a comprehensive platform developed by GSK and IQVIA for use
by public health officials, industry leaders and medical
professionals to strengthen vaccination data transparency, raise
awareness and publicly share vaccination trends to aid improvements
in routine adult vaccinations to create healthier communities
across the US. This resource will provide frequent and relevant
data on trends to focus and enhance public health efforts.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220808005462/en/
To learn more, please visit
www.vaccinetrack.com. (Graphic: Business Wire)
Judy Stewart, GSK Senior Vice President and Head of US
Vaccines said: “For the first time, Vaccine Track brings
quarterly data tracking and trends together in a comprehensive
platform for immunization partners, decision makers and
stakeholders. Our goal for Vaccine Track is to support the return
to pre-pandemic vaccination rates for adults and to go beyond by
empowering the vaccine and public health community with frequently
updated, actionable information to get ahead of disease
together.”
Collective experience throughout the COVID-19 pandemic has
elevated the public's understanding of the value of vaccines and
the importance of data in helping to prevent disease and death,
especially in adult and older adult populations. Vaccination rates
for CDC-recommended vaccines were low before the pandemic and
despite heightened awareness, adult immunization rates
significantly declined during the pandemic, compounding already low
rates. This is significant because even small drops in
immunizations can lead to a resurgence of disease.
“Access to this new set of data, paired with existing data,
provides an opportunity for the public health community to work
together to increase immunization and prevent disease and death,”
said Stewart.
The Vaccine Track platform will enable users to:
- Identify vaccination trends for adults 19+ in the US across
multiple vaccines
- Scan immunization claims data nationally and sub-nationally
across years
- Track trends based on 2019 pre-COVID-19 baseline vaccination
uptake
- Highlight where differences exist based on demographics (e.g.,
age, race/ethnicity, gender, payer type)
Matthew Guagenty, SVP & GM, Commercial Solutions at IQVIA
said: “We are proud to partner with GSK to power Vaccine Track
with rich longitudinal data and national-level analytics that we
hope will help immunization partners as well as national and local
decision-makers and stakeholders work towards solutions to improve
vaccination rates. Ultimately, the goal is to improve health
outcomes across the nation, including underserved populations.”
Vaccine Track data insights revealed sustained decline of
recommended adult immunizations, excluding flu vaccinations, across
the US during the pandemic. This was particularly true for minority
populations, which already showed lower rates of immunization
pre-pandemic.
- National trends for adults aged 19 and older continue to remain
below pre-pandemic 2019 baselines with an average decrease of
18% through 2021 in overall claims for recommended vaccines,
excluding influenza. Vulnerable populations may be especially
impacted by this trend
- Average monthly overall claims data through 2021 for
recommended vaccines (excluding influenza) were
12-42% below by payer compared to a 2019 baseline
- For Medicare, analysis found more than 30% reduction in overall
claims for recommended vaccines among Black and Hispanic
populations between 2019 and 2021.This highlights the significant
potential impact and exacerbation on disparities in immunization
rates in Medicare due to the pandemic
- At the state level, as of December 2021 nearly half of the
states in the US were facing greater than 30% reductions in overall
claims for recommended vaccines from 2019 pre-pandemic levels
Temi Folaranmi, MD, Vice President and Vaccines Therapeutic
Area Head, US Medical Affairs, GSK said: “Recommended
immunization is an essential component of preventive care that
protects both individuals and communities from vaccine-preventable
disease. Through strengthened data transparency and collaboration,
GSK is committed to supporting the public health community in
developing long-lasting solutions with key partners. Together, we
need to address the challenges to increase vaccination rates and
the necessary public policy reforms in order to create healthier
communities.”
About Vaccine Track
Vaccine Track is a comprehensive platform provided by GSK, in
partnership with IQVIA, for use by public health officials,
industry leaders and medical professionals to strengthen
vaccination data transparency, raise awareness and publicly share
vaccination trends. Containing comprehensive claims data about
routine adult (age 19+) vaccines, Vaccine Track currently spans
information from January 2019 to December 2021 and will be updated
on a quarterly basis. Information is sourced from medical claims
data and longitudinal prescription data; both datasets are
de-identified for research purposes. Medical claims data is
collected from services performed in physicians’ offices;
longitudinal prescription data sourced from retail and mail
pharmacies, as well as long-term care facilities. Vaccines
administered in institutional or hospital settings, as well as
through certain other settings or programs, are not accounted for
in projections.
About GSK
GSK is a global biopharma company with a purpose to unite
science, technology, and talent to get ahead of disease together.
Find out more at gsk.com/company.
About IQVIA
IQVIA (NYSE: IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 82,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behavior and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK’s Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales: No. 3888792
Registered Office: 980 Great West Road Brentford,
Middlesex TW8 9GS
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220808005462/en/
GSK enquiries Media: Kathleen Quinn +1 202 603 5003
(Washington DC) Sean Clements +1 215 740 3088 (Philadelphia) Alison
Hunt +1 540 742 3391 (Washington DC) Investor Relations: Nick Stone
+44 (0) 7717 618834 (London) James Dodwell +44 (0) 20 8047 2406
(London) Mick Readey +44 (0) 7990 339653 (London) Josh Williams +44
(0) 7385 415719 (London) Jeff McLaughlin +1 215 751 7002
(Philadelphia)
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024